BioSpace News Archive

ProMetic announced today that an orphan drug designation status has been granted to its Plasminogen for the treatment of IPF by the FDA.

Genmab announced today that at a board meeting the board decided to grant 49,680 restricted stock units to members of the board of directors, management and employees of the company as well as the company’s subsidiaries and 139,597 warrants to management and employees of the company as well as the company’s subsidiaries.

Targovax today announces that TG02 has passed the initial planned safety review in the phase Ib clinical mechanism-of-action trial evaluating TG02, and TG02 in combination with the checkpoint inhibitor KEYTRUDA, in patients with confirmed RAS-mutated colorectal cancer.

BeiGene today announced that the first patient was dosed in a pivotal Phase 2 clinical trial of pamiparib in Chinese patients with advanced ovarian cancer.

Under the terms of the Purchase Agreement, the Buyers have agreed to purchase an aggregate of $30M of units, inclusive of funds being advanced by an affiliate of Ospraie as bridge financing under a convertible promissory note.

EDAP TMS S.A. (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital, Istanbul, Turkey, using the Company’s Focal One Robotic HIFU device.

Innovation Pharma today is pleased to provide an update on the developmental plan for Brilacidin, its first-in-class defensin-mimetic drug candidate, for the prevention and treatment of Oral Mucositis.

Opiant today reports that new pre-clinical data supporting the continued development of OPNT005 as a heroin vaccine were published online in the Journal of Medicinal Chemistry.

The objective of the study is to evaluate the safety and efficacy of P-BCMA-101 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose.

Catalyst Biosciences today announces that the Korean MFDS has approved a protocol amendment to omit single dose Cohort 4 and move directly to multi-dose Cohort 5 at 150 IU/kg daily, in the ongoing Phase 1/2 multi-dose study of CB 2679d/ISU304, Catalyst’s highly potent next-generation coagulation Factor IX variant in individuals with severe hemophilia B.